Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tijana Randic"'
Autor:
Tijana Randic, Stefano Magni, Demetra Philippidou, Christiane Margue, Kamil Grzyb, Jasmin Renate Preis, Joanna Patrycja Wroblewska, Petr V. Nazarov, Michel Mittelbronn, Katrin B.M. Frauenknecht, Alexander Skupin, Stephanie Kreis
Publikováno v:
Cell Reports, Vol 42, Iss 7, Pp 112696- (2023)
Summary: Treatment options for patients with NRAS-mutant melanoma are limited and lack an efficient targeted drug combination that significantly increases overall and progression-free survival. In addition, targeted therapy success is hampered by the
Externí odkaz:
https://doaj.org/article/2e3d1c75d71042c3b96880a1c97c6298
Autor:
Vincent Gureghian, Hailee Herbst, Ines Kozar, Katarina Mihajlovic, Noël Malod-Dognin, Gaia Ceddia, Cristian Angeli, Christiane Margue, Tijana Randic, Demetra Philippidou, Milène Tetsi Nomigni, Ahmed Hemedan, Leon-Charles Tranchevent, Joseph Longworth, Mark Bauer, Apurva Badkas, Anthoula Gaigneaux, Arnaud Muller, Marek Ostaszewski, Fabrice Tolle, Nataša Pržulj, Stephanie Kreis
Therapy Induced Senescence (TIS) leads to sustained growth arrest of cancer cells. The associated cytostasis has been shown to be reversible and cells escaping senescence further enhance the aggressiveness of cancers. Together with targeted therapeut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfc6e5557f14569079e2e1e54f858f28
https://doi.org/10.1101/2023.02.13.528114
https://doi.org/10.1101/2023.02.13.528114
Autor:
Tijana Randic, Stefano Magni, Demetra Philippidou, Kamil Grzyb, Jasmin Renate Preis, Christiane Margue, Petr Nazarov, Michel Mittelbronn, Katrin Frauenknecht, Alexander Skupin, Stephanie Kreis
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5ab066153c25782cf293ece87e262d0
https://doi.org/10.2139/ssrn.4295386
https://doi.org/10.2139/ssrn.4295386
Publikováno v:
Cancer Treatment Reviews. 99:102238
Genetic alterations affecting RAS proteins are commonly found in human cancers. Roughly a fourth of melanoma patients carry activating NRAS mutations, rendering this malignancy particularly challenging to treat. Although the development of targeted a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b23ea34d0bdcb6329f52fb2a9492464
https://doi.org/10.1016/j.ctrv.2021.102238
https://doi.org/10.1016/j.ctrv.2021.102238